Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

AM-111 in the Treatment of Acute Inner Ear Hearing Loss (HEALOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02561091
Recruitment Status : Completed
First Posted : September 25, 2015
Last Update Posted : October 16, 2017
Information provided by (Responsible Party):
Auris Medical, Inc. ( Auris Medical AG )

Brief Summary:
The purpose of this research study is to test the effectiveness and safety of the study drug, AM-111. AM-111 is tested for the treatment of sudden sensorineural hearing loss where the cause is unknown.

Condition or disease Intervention/treatment Phase
Hearing Loss Other: Placebo Drug: AM-111 0.4 mg/ml Drug: AM-111 0.8 mg/ml Phase 3

Detailed Description:
This phase III study is assessing the drug's safety and is aiming to demonstrate efficacy of intratympanic AM-111 injections in the treatment of severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL). The active pharmaceutical ingredient of AM-111 is the JNK inhibitor (D-JNKI-1), a synthetic peptide consisting of 31 D-amino acids, which acts as a c-Jun N-terminal kinase (JNK) ligand.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 256 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss
Study Start Date : November 2015
Actual Primary Completion Date : September 2017
Actual Study Completion Date : September 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo gel for intratympanic use
Other: Placebo
Experimental: AM-111 0.4 mg/ml
AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
Drug: AM-111 0.4 mg/ml
Experimental: AM-111 0.8 mg/ml
AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
Drug: AM-111 0.8 mg/ml

Primary Outcome Measures :
  1. Pure tone average (PTA; average of the hearing threshold of three contiguous most affected hearing frequencies in dB) [ Time Frame: Day 28 ]
    Assessment with pure tone audiometry/ Measurement at 8 frequencies/ Final outcome is the absolute improvement in PTA from D0 to D28

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Unilateral ISSNHL with onset within 72 hours prior to study treatment;
  2. Mean hearing threshold of equal to or worse than (≥) 60 dB averaged across the 3 most affected contiguous air conduction audiometric pure tone frequencies ("pure tone average", PTA);*
  3. Mean hearing loss of equal to or worse than (≥) 40 dB averaged across the air conducted PTA frequencies compared with the unaffected contralateral ear or reference values from a pre-existing audiogram or ISO 7029;2000 norm values in case of asymmetric hearing prior to the ISSNHL incident;
  4. Age ≥ 18 and ≤ 65 years on the day of screening;

Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  1. Bilateral ISSNHL;
  2. Acute hearing loss from noise trauma, barotrauma or head trauma;
  3. History of autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops or Menière's disease in the affected ear;
  4. History of chronic inflammatory or suppurative ear disease or cholesteatoma in the affected ear;
  5. History of acoustic neuroma or other retrocochlear damage in the affected ear;
  6. History of otosclerosis in the affected ear;
  7. Suspected perilymph fistula or membrane rupture in the affected ear;
  8. Congenital hearing loss;
  9. History of ISSNHL in the past 2 years;
  10. Otitis media or otitis externa that is ongoing or ended within 7 days prior to study treatment;

Other protocol-defined exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02561091

Layout table for location information
Please check link to study webpage below for more study sites
Sofia, Bulgaria
Sponsors and Collaborators
Auris Medical AG
Additional Information:
Layout table for additonal information
Responsible Party: Auris Medical AG Identifier: NCT02561091    
Other Study ID Numbers: AM-111-CL-13-01
First Posted: September 25, 2015    Key Record Dates
Last Update Posted: October 16, 2017
Last Verified: August 2017
Keywords provided by Auris Medical, Inc. ( Auris Medical AG ):
Hearing Loss, Sensorineural
Ear Diseases
Hearing Disorders
Otorhinolaryngologic Diseases
Sensation Disorders
Signs and Symptoms
Hearing and Speech impairment
Hearing Loss, Unilateral
Additional relevant MeSH terms:
Layout table for MeSH terms
Hearing Loss
Hearing Loss, Sensorineural
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases